Idiopathic Pulmonary Fibrosis Market Size, Share, Analysis, Growth, Trends, Industry Report 2023-2032 | F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC,

Spread the love

The Business Research Company’s Idiopathic Pulmonary Fibrosis Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Idiopathic Pulmonary Fibrosis Global Market Report 2023 evaluates idiopathic pulmonary fibrosis market size, growth rate, drivers, trends, and major companies.

The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=12579&type=smp

The global idiopathic pulmonary fibrosis market is expected to grow from $3.67 billion in 2022 to $3.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The idiopathic pulmonary fibrosis market is expected to reach $4.89 billion in 2027 at a CAGR of 5.9%.

The rise in the prevalence of fibrotic disease is expected to drive the growth of the idiopathic pulmonary fibrosis market going forward. Fibrotic diseases, also known as fibrosis, refer to a group of medical conditions characterized by the excessive formation and accumulation of fibrous connective tissue in various organs or tissues in the body. Idiopathic pulmonary fibrosis drugs help reduce lung fibrosis and inflammation by targeting multiple signaling pathways involved in fibrosis. For instance, in December 2022, according to the American Lung Association, a US-based lung association, there were around 207,000 people affected in the United States and approximately 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year, which is more common in men than women and mainly affects people over 50 years of age. Therefore, the rise in the prevalence of fibrotic disease drives the idiopathic pulmonary fibrosis market.

Get More Information On The Idiopathic Pulmonary Fibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

The idiopathic pulmonary fibrosis market segments in the report are:

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals and Clinics, Other End Users

The table of contents in TBRC’s idiopathic pulmonary fibrosis market report includes

1. Executive Summary

2. Idiopathic Pulmonary Fibrosis Market Characteristics

3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

4. Idiopathic Pulmonary Fibrosis Market – Macro Economic Scenario

5. Idiopathic Pulmonary Fibrosis Market Segmentation

.

.

.

26. South America Idiopathic Pulmonary Fibrosis Market

27. Brazil Idiopathic Pulmonary Fibrosis Market

28. Middle East Idiopathic Pulmonary Fibrosis Market

29. Africa Idiopathic Pulmonary Fibrosis Market

30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

Top Major Players:

  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →